Atopic Dermatitis Upcoming Therapies

Sep 23, 2025

FDA Approves Merck’s KEYTRUDA QLEX for Subcutaneous Use Across Multiple Solid Tumors Merck announced that the FDA has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration in adults across most of KEYTRUDA’s approved solid tumor indications. Unlike the intravenous...

Jul 19, 2024

After a few days of investor anxiety, Arcutis Biotherapeutics announced that the FDA has approved ZORYVE for a new indication: atopic dermatitis. The FDA was scheduled to announce its decision on ZORYVE (roflumilast) for this new use on the 7th of this month, but the date passed without news. In an uncommon move to...

May 20, 2024

Atopic dermatitis is common worldwide, and people of all ages, from newborns to adults 65 and older, live with this condition. The World Health Organization (WHO) Global Burden of Diseases initiative estimates more than 230 million people globally have atopic dermatitis and that skin diseases are the fourth leading...

Dec 31, 2019

Dupilumab, a monoclonal antibody, is administered in the form of injection for the treatment of Atopic dermatitis (Eczema) in adults and children of age 12 and old. The injection works by hampering the substance in the body, which produces allergic reactions. Dupilumab is a receptor-antagonist and binds to the alph...